1 R01 CA119125-01/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Page 1

Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.

Garzotto M, Higano CS, O'Brien C, Rademacher BL, Janeba N, Fazli L, Lange PH, Lieberman S, Beer TM. Garzotto M, et al. Cancer. 2010 Apr 1;116(7):1699-708. doi: 10.1002/cncr.24960. Cancer. 2010. PMID: 20143429 Free PMC article. Clinical Trial.

ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21.

Geng H, Rademacher BL, Pittsenbarger J, Huang CY, Harvey CT, Lafortune MC, Myrthue A, Garzotto M, Nelson PS, Beer TM, Qian DZ. Geng H, et al. Cancer Res. 2010 Apr 15;70(8):3239-48. doi: 10.1158/0008-5472.CAN-09-3186. Epub 2010 Apr 13. Cancer Res. 2010. PMID: 20388787 Free PMC article.

CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.

Qian DZ, Rademacher BL, Pittsenbarger J, Huang CY, Myrthue A, Higano CS, Garzotto M, Nelson PS, Beer TM. Qian DZ, et al. Prostate. 2010 Mar 1;70(4):433-42. doi: 10.1002/pros.21077. Prostate. 2010. PMID: 19866475 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Search Page

Filters